Applied Biosystems has been put at a big disadvantage in an important sequencing patent issue after a key licensing partner was recently named the junior party in a patent interference review triggered by the allowance of an Enzo Biochem patent on DNA sequencing technology.
 
According to a patent attorney with experience in the interference review process, statistics show that companies named a junior party have little chance of winning the US patent office’s designation as original inventor.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.